首页 | 本学科首页   官方微博 | 高级检索  
     


The Outcome of Surgical Resection Versus Assignment to the Liver Transplant Waiting List for Hepatocellular Carcinoma
Authors:Jean-Pierre?E.?N.?Pierie,Alona?Muzikansky,Kenneth?K.?Tanabe,Mark?J.?Ott  author-information"  >  author-information__contact u-icon-before"  >  mailto:Idmott@ihc.com"   title="  Idmott@ihc.com"   itemprop="  email"   data-track="  click"   data-track-action="  Email author"   data-track-label="  "  >Email author
Affiliation:(1) Department of Gastro-Intestinal Surgery, Medical Center, Leeuwarden, Henri Dunantweg Z, 8934, AD Leeuwarden, The Netherlands;(2) Center of Cancer Statistics, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts, 02114;(3) Department of Surgical Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts, 02114;(4) Department of Surgery, Latter-Day Saints Hospital, 324 Tenth Avenue, Suite 184, Salt Lake City, UT 84103, USA
Abstract:Background Optimal management of patients with hepatocellular carcinoma (HCC) is controversial. This study was conducted to evaluate the outcome of tumor resection versus assignment to a liver transplant waiting list (WL) in patients with HCC.Methods Prospectively collected patient data from 1970 to 1997 on 313 patients with HCC were retrospectively analyzed by multivariate analysis to determine the effect of liver disease, method of treatment, and tumor-related factors on survival.Results A total of 199 patients underwent nonsurgical palliative care (PC), 81 underwent partial liver resection (LR), and 33 were assigned to a liver transplant WL, of which 22 received a donor liver. A total of 91%, 53%, and 91% of the patients had cirrhotic livers in the PC, LR, and WL groups, respectively (P < .001). In the LR group, the absence of a tumor capsule (P < .0001) and a poorly differentiated tumor (P = .027) were both adverse prognostic factors. In the WL group, hepatitis B (P = .02) and American Joint Committee on Cancer tumor stage III (P = .019) were adverse prognostic factors. The 3-year survival rates were 4%, 33%, and 38% for the PC, LR, and WL patients, respectively (P < .0001). The 3-year survival rate in the LR patients was 51% in patients without cirrhosis and 15% in patients with cirrhosis (P < .0001).Conclusions Patients with locally unresectable tumors, distant disease, or both will continue to receive PC. Patients assigned to liver transplant WLs run the risk of not receiving a donor liver, in which case their survival is predicted to be poor. Survival after resection in a group of patients with advanced tumors is worse than that after transplantation; however, shortages of donor livers presently preclude transplantation in this population of patients.
Keywords:Hepatocellular carcinoma  Resection  Transplantation  Outcome
本文献已被 PubMed SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号